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THE ROLE OF CCAAT DISPLACEMENT PROTEIN IN NEUTROPHIL-SPECIFIC GENE
EXPRESSION. Aimee Lee, Arati Khanna-Gupta and Nancy Berliner. Section of Hematology,
Department of Internal Medicine, Yale University, School of Medicine, New Haven, CT.

CCAAT displacement protein (CDP) is a highly conserved, ubiquitously expressed
homeodomain protein with extensive homology to the Drosophila cut protein. CDP contains
three conserved DNA-binding repeats called cut repeats, as well as a conserved homeodomain
sequence. CDP is a transcriptional repressor of several developmentally regulated genes
including gp91-phox, CCAAT enhancer binding protein epsilon (C/EBPs), and its
downstream targets the neutrophil secondary granule proteins (SGPs), including lactoferrin
(LF). We have previously shown that CDP binds to and represses both the C/EBPs and LF
gene promoters, thereby preventing expression of SGPs both directly and indirectly. CDP
overexpression represses expression of SGPs in 32Dcl3 cells, a murine myeloid cell line that
undergoes differentiation in response to G-CSF stimulation. Several attempts at generating a
CDP knockout mouse have been undertaken, but all have produced incomplete knockouts. I
generated short hairpin RNA (shRNA) constructs to knock down CDP in 32Dwtl8 cells,
which contain a chimeric G-CSF receptor linking the intracellular domain of the G-CSF
receptor with the extracellular component of the erythropoietin (EPO) receptor, and
differentiate in response to EPO. CDP repression in clones expressing the shRNA for CDP
appears to correlate with increased LF expression in uninduced cells. Control clones do not
express LF until induced with EPO for several days. The knockdown of CDP does not appear
to affect the expression of C/EBPs, suggesting that LF expression reflects direct modulation
of CDP binding to its promoter and is not an indirect effect of increased C/EBPs expression.
This suggests that CDP can function as the sole negative regulatory element for LF gene
expression, and that relief of CDP repression can increase LF expression independent of
positive regulatory factors.
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Introduction

Mature cells in all hematopoietic lineages are required for proper functioning of the adult
mammal. The generation of mature neutrophils from hematopoietic stem cell (HSC)
precursors is a process which is still incompletely understood. The basic model for
formation of mature blood products from HSCs involves the regeneration of HSCs, as
well as formation of precursors for other hematopoietic lineages. As a hematopoietic cell
differentiates, it loses proliferative potential and gains specific characteristics of endstage
mature cells. The HSC gives rise to both the common lymphoid progenitor (CLP) and
common myeloid progenitor (CMP). The CMP further differentiates into the myeloid
erythroid progenitor (MEP), which gives rise to megakaryocytes, basophils and
eosinophils, and the granulocyte/macrophage progenitor (GMP), which gives rise to both
monocyte and granulocyte precursors.

To ensure a correct number of mature cells in each lineage, hematopoiesis is tightly
regulated by many different cytokines and transcription factors (1,2). Granulocytes and
monocytes originate from a common progenitor cell, but the precise mechanism by which
the terminal products of maturation are formed is still unclear. Although granulocytes
and monocytes share several transcription factors with overlapping functions, other
factors will tip the balance in favor of producing either granulocytes or monocytes
(reviewed in 1). PU.l, Spl and the CCAAT enhancer binding protein (C/EBP) family of
transcription factors are shared transcription factors. Maf and Jun family members may
favor the development of the monocyte lineage, while higher levels of C/EBPs could
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direct the formation of neutrophil granulocyte precursors. The terminal maturation of
neutrophils requires PU.l, C/EBPs (especially C/EBPs), Spl and retinoic acid receptors
(RARs). The milieu is further enhanced by the presence of a variety of cytokines, or
colony stimulating factors (CSFs) (reviewed in 2). In myeloid lineages, GM-CSF
furthers the development of clones of granulocytes and macrophages, M-CSF stimulates
production of macrophages, and G-CSF induces granulocyte formation. Interleukin-3
(IL-3) can stimulate development of eosinophils, mast cells, megakaryocytes and
erythroid cells in addition to producing macrophages and granulocytes.

Granulocyte differentiation can be followed morphologically through phenotypic changes
in the neutrophil nucleus, and biochemically through changes in cytoplasmic granule
expression (Figure 1). Condensation of chromatin eventually transforms the immature
myeloblast nucleus into the multilobed nucleus of a mature neutrophil. Biochemically,
the promyelocyte is characterized by expression of primary “nonspecific” granules which
contain myeloperoxidase (MPO). The transition between promyelocyte and myelocyte is
marked by expression of secondary “specific” granule proteins (SGPs) such as lactoferrin
(LF), neutrophil collagenase (NC), neutrophil gelatinase (NG), and transcobalmin 1
(TCI) (3). Although expression of SGP mRNA and protein is coordinately upregulated
at the promyelocyte to myelocyte transition, the genes themselves are physically unlinked
(4). This suggests a coordinated and stage-specific upregulation presumably induced by
common transcription factors that result in SGP gene expression.

.
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Figure 1. Neutrophil Maturation. Neutrophil maturation proceeds from the immature
myeloblast to the segmented neutrophil. The morphological changes are paralleled by
changes in granule protein expression. Figure courtesy of Arati Khanna-Gupta.

Granule proteins formed at the same stage in development will sort into the same
granules (5). One can then define the neutrophil developmental stage by the biochemical
contents of the granules. Expression of SGPs serves as a marker for terminal myeloid
differentiation (6). C/EBP epsilon (C/EBPs) contributes to the morphological and
functional differentiation of neutrophils by upregulating SGP expression. Clinically,
absence of SGPs or abnormal SGP expression is found in acute myelogenous leukemia
(AML), myelodysplastic syndrome (MDS), and specific granule deficiency (SGD). All
are associated with disruptions in normal myeloid differentiation.
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In previous studies, our laboratory has demonstrated that a known negative regulator of
transcription, CCAAT displacement protein (CDP) binds to the LF promoter and
represses its transcription (7). In further studies, it was shown that CDP not only exerts
these direct effects on the LF promoter, but also indirectly represses SGP expression by
repressing C/EBPs (8). The overexpression of CDP inhibits expression of SGP genes in
32Dcl3 cells, an IL-3 dependent murine myeloid cell line that undergoes differentiation
in response to IL-3 withdrawal and G-CSF stimulation (9). Moreover, LF is not
expressed in NB4 cells, a human acute promyelocytic cell line which contains the
t(l5; 17) PML-RARa translocation. While CDP binding to the LF promoter is abolished
in 32Dcl3 cells coincident with LF expression, CDP has been found to remain bound to
the LF promoter in NB4 cells after morphological differentiation following ATRA
induction. This suggests that decreased CDP binding to the LF promoter is necessary and
permissive for LF gene expression.

CDP is a highly conserved, ubiquitously expressed homeodomain protein with extensive
homology to the Drosophila cut protein (reviewed in 10). The protein contains three
highly conserved DNA-binding repeats called cut repeats (CR1-3), as well as a conserved
homeodomain (HD) area (11) (Figure 2), which mediate its DNA binding capacity. CDP
is a 350 kb gene with 33 exons (12) which maps to chromosome 7q22 (13).
Rearrangements in 7q22 have been seen in AML, MDS and uterine leiomyomas,
suggesting that CDP may function as a tumor suppressor gene (reviewed in 10).
However, this hypothesis remains unproven.
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Figure 2. Schematic drawing of CDP. CDP contains 3 cut repeats (CR) as well as a
homeodomain region (HD). These 4 conserved areas mediate DNA binding activity.

CDP is a negative regulator of several developmentally regulated myeloid genes,
including gp91-phox, a component of the neutrophil respiratory burst NADPH oxidase
complex (11). Interestingly, gp91-phox is expressed earlier than SGPs in myeloid
differentiation. The mechanism by which CDP mediates this temporal gene regulation is
currently unknown. Recent studies have shown that CDP cannot bind DNA as a
monomer and that several splice isoforms of CDP exist (14). Different combinations of
CR1-3 and HD, as well as variations in splicing, may account for the differential effects
of CDP. Phosphorylation and recruitment of histone deacetylases have also been
proposed as mechanisms contributing to the variety in CDP function (15,16).

Our laboratory has previously demonstrated that CDP binds to and represses both the
C/EBPe and LF promoters (7, 8). Overexpression of CDP leads to repression of SGPs in
mouse and human cell lines without inhibiting morphological differentiation. Due to the
size of the CDP gene several attempts at generating a CDP knockout mouse have been
unsuccessful, generating partial knockouts each time. The ACR1 mouse, in which the
first cut repeat has been deleted, exhibits a mild phenotype consisting of curly vibrissae.
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wavy hair, and a high degree of pup loss most likely due to feeding difficulties (17).
ACR3HD, displays partial neonatal lethality with survivors surrendering to a wasting
disease within 2-3 weeks. Interestingly, they also display myeloid hyperplasia and
lymphoid apoptosis (18).

As generating a complete knockout of CDP has proven to be a difficult task, we decided
to employ a PCR-based RNA interference (RNAi) strategy to attempt to knock-down
CDP in myeloid cells. RNAi harnesses the cell’s inherent ability to degrade RNA from
exogenous sources in a targeted manner. Several methods are available to produce RNAi
in mammalian cells, including synthesized small interfering RNAs (siRNAs), in vitro
RNAselll processed dsRNA, and short hairpin RNAs (shRNAs). I chose to use a vectorbased shRNA strategy for several reasons: 1) the shRNA fragments are relatively simple
to create and clone into appropriate vectors, 2) this strategy is more cost-effective than
chemically synthesized siRNAs, 3) a vector-based strategy allows for the generation of
stable cell lines, and 4) this method was previously successful in hematopoietic cell lines.
A myeloid cell line in which CDP is knocked-down will provide valuable and more
complete information on the role CDP plays in the developing neutrophil.
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Hypothesis and Specific Aims

The aim of this project is to characterize and define the role of CDP in myeloid
differentiation using normal and leukemic cells as models. I proposed to perform a
functional knockout of mouse CDP by utilizing short hairpin RNAs (shRNAs) to degrade
CDP mRNA, thus preventing the formation of a final protein product. I hypothesize that,
as SGP expression occurs at the same stage in differentiation yet the genes themselves are
physically unlinked, SGP expression is regulated by shared transcription factors that
direct the coordinate expression of SGPs during normal myeloid differentiation. I further
hypothesize that one of these critical transcription factors is CDP. As transcriptional
regulation of granulopoiesis is disrupted in AML, SGD and MDS, CDP must play an
integral role in myeloid differentiation. The ultimate goal of this project will be to
analyze the CDP knock down cells using a myeloid specific cDNA microarray generated
in the Berliner Lab in collaboration with Dr. Arch Perkins (Dept of Pathology, Yale
University School of Medicine). These analyses will shed light on all genes regulated by
CDP during myeloid differentiation, and will provide valuable and more complete
information on the role CDP plays in the developing neutrophil.
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Methods

Short Hairpin RNA (shRNA) vector construction. shRNA constructs were generated as
previously described by Hannon (19, 20). Briefly, the group uses a PCR-based method to
create generate vector-based RNA interference. A web based RNA oligonucleotide
retriever was developed by the group, and interested researchers enter a nucleic acid
accession number for the target gene. The web based program then designs an
oligonucleotide which best targets future degradation of mRNA. shRNA design does not
correlate with the location of cut repeats or HD (Figure 3).
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Figure 3. Location of shRNA constructs in relation to cut repeats and

homeodomain. shRNA constructs are targeted to the 5’ and 3’ ends of each gene. An
additional site in the middle of the gene is targeted in the human CDP shRNA construct.
None of the regions targeted by shRNA are known DNA-binding regions.

Instead, the hairpin is designed in the most efficient location for RNAi degradation of
mRNA. Oligonucleotides were made by the Oligonucleotide Synthesis Laboratory
(Department of Pathology, Yale University) then used as the forward 5’ PCR primer.
while another oligonucleotide which contains the U6 promoter sequence is used as the 3’
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primer (Figure 4). PCR with DMSO using the pGEM-Zeo-U6 vector as template was
performed, then the PCR fragment was cloned using TOPO cloning (Invitrogen,
Carlsbad, CA) for use in transient transfections. For stable transfections, the PCR
fragment was subcloned into the GFP-containing MigRl vector (Figure 5).

Sequencing
Transient transfection into NIH-3T3
fibroblast cells to test shRNA constructs

S'

Subclone into MigRl vector

I
Transfect into 32Dwt18 cells

Figure 4. shRNA Construction. As outlined in the text, forward and reverse PCR
primers were developed based on the Hannon method. PCR fragments containing the
shRNA were first cloned into the TA vector and subcloned into MigRl.
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Figure 5. MigRl vector. The MigRl vector is 6056 bp in size and contains genes for
ampicillin resistance as well as GFP driven by an IRES. The shRNA PCR fragment was
cloned into the EcoR I and Bgl II restriction sites.

Tissue culture. NIH3T3 cells were grown and maintained in Dulbecco’s Modified
Eagle’s Medium (DMEM) with 10% Fetal Calf Serum (FCS, Gemini Bio-products).
32Dwtl8 cells were maintained in Iscove’s Modified Dulbecco Medium (IMDM)
supplemented with 10% Fetal Bovine Serum (FBS, Gemini Bio-products) and 10%
WEHI-3D-conditioned medium. All growth media were supplemented with 5U/mL
penicillin, 5pg/mL streptomycin sulfate and 2mM L-glutamine.

Transient transfection ofNIH3T3 cells. NIH3T3 cells were plated at a density of 1.5 x
106 cells per 10 cm plate the day prior to transfection in DMEM with 10% FCS. The
morning of transfection, cells were washed once with PBS, and then incubated in
Optimem (Gibco). 1 Opg DNA was added to a mixture of 3pL Fugene 6 Transfection
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Reagent (Roche, Indianapolis, IN) and Optimem to a total volume of lOOpL. Cells were
incubated overnight in Optimem and DNA mixture, and then medium was changed to
DMEM the following DNA. Cells were harvested 72 hours after transfection.

Stable transfection of 32Dxvtl8 cells. Exponentially growing 32Dwtl8 cells (1.0 x 107)
were washed twice with PBS and resuspended in 180pL HEPES-buffered saline. lOpg
of DNA was transfected by electroporation. The electroporated cells were resuspended
in IMDM supplemented with 10% WEHI-3D-conditioned medium and 10% FBS.

Flow cytometry. 7 x 106 32Dwtl8 cells were washed in PBS and resuspended in IMDM
supplemented with 10% WEHI-3D-conditioned medium and 2.5% FBS with propidium
iodide to a final concentration of 2pg/mL. Cells were sorted by Mr. Rocco Carbone
(Yale Cancer Center shared facility) and collected in 4 mL IMDM supplemented with
10% WEHI-3D-conditioned medium and 10% FBS.

Induction of differentiation. Stably transfected 32Dwtl8 cells were collected in growth
medium (GM) for day 0 samples, or induced to differentiate in induction medium (IM)
IMDM supplemented with 10% FBS without 10% WEHI-3D-conditioned medium, and
addition of lU/mL EPO for 4 days. Media was replaced every 3 days during the
induction procedure, and cell densities were maintained at or below 1.0 x 106 cells/mL.
All growth media were supplemented with 5U/mL penicillin, 5pg/mL streptomycin
sulfate and 2mM L-glutamine.
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Cytospins. 1.0 x 104 cells were centrifuged at low speed onto a microscope slide and
stained with Wright-Geimsa staining.

Growth Curve Analysis. 1 x 105 cells were grown in regular growth medium, induced to
differentiate with EPO, or grown in IMDM without WEHI-3D-conditioned medium.
Cell densities were maintained at or below 1.0 x 106 cells/mL. Cells were counted daily
using a hemacytometer (Reichert, Buffalo, NY) with Trypan Blue Stain 0.4% (Gibco).

Isolation of total RNA. 5-10 x 106 cells were pelleted at 1250 rpm and then homogenized
in 1 mL TRIzol reagent (Invitrogen). Resuspended cells were incubated for 5 minutes at
room temperature then 0.2 mL chloroform was added per 1 mL TRIzol reagent. Samples
were vigorously shaken and allowed to stand at room temperature for 2 minutes.
Samples were then centrifuged at 12,000 RPM at 4°C for 15 minutes. The aqueous phase
was transferred to a new tube and 0.5 mL isopropanol added, then incubated at room
temperature for 10 minutes. Samples were centrifuged at 12,000 RPM at 4°C for 1015min, supernatant removed and washed once with 75% EtOH. The RNA pellet was
resuspended in DEPC-H2O and stored at -70°C until used.

Polymerase Chain Reaction (PCR). 100 ng of total RNA was mixed with 50 mg of oligo
dT, denatured at 65°C for 10 minutes, and mixed with reverse transcription buffer,
dNTPs, RNAsin, and dithiothreitol (DTT) in a final volume of 50 pL. Reactions were
then incubated with reverse transcriptase for 1 hour at 37°C. 1 pL of the resultant cDNA
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was then subjected to 30-40 cycles of PCR under standard conditions with 100 ng of
appropriate primers and 1 to 3 U Taq Polymerase.

Preparation of nuclear extracts. 1.0 x 107 cells were centrifuged at 4°C. Cells were
washed twice in ice-cold phosphate buffered saline (PBS) and once in Buffer A (10
mmol/L HEPES-KOH (pH 7.9), 1.5 mmol/L MgCl2, 10 mmol/L KC1, 0.5 mmol/L DTT,
and 0.5 mmol/L phenylmethylsulfonyl fluoride (PMSF). Cells were then lysed following
a 5-minute incubation on ice in Buffer A with 0.1% Nonidet P-40, and then centrifuged at
4°C for 15 minutes to recover nuclei. Nuclei were then lysed in high-salt Buffer C (20
mmol/L HEPES-KOH (pH 7.9), 10% glycerol, 420 mmol/L NaCl, 10 mmol/L KC1, 0.2
mmol/L EDTA, and 0.5 mmol/L DTT) and nuclear extracts were recovered by
centrifugation for 15 minutes at 4°C. Aliquots of nuclear protein were analyzed for total
protein concentration, then frozen immediately and stored at -70°C until used.

Preparation of whole cell extracts. 1x10 cells were centrifuged at 4°C. Cells were
washed once with 4°C phosphate buffered saline (PBS) and resuspended in 100 pL RIPA
Lysis Buffer (Upstate Biotechnology, Lake Placid, NY) with protease inhibitor. Cells
were incubated on ice for 30 minutes, then centrifuged at 10,000 x g for 10 minutes in
4°C. The supernatant was transferred to a new tube, analyzed by spectrophotometry for
concentration, and frozen immediately on dry ice. Samples were maintained at -70°C
until used.
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Western Blot. 15 pg protein were separated on a 4-12% Bis-Tris Gel (Invitrogen) and
transferred to PVDF membrane (Immobilon-P; Millipore, Bedford, MA). Membranes
were blocked in TST (20mM Tris [ph 7.5], 150 mL NaCl, 0.1% Tween-20) with 5%
nonfat dry milk for 1 hour at 25°C. For detection of CDP, a mouse monoclonal antibody
was incubated with the membrane in TST/5% milk overnight at 4°C at a concentration of
1:1000. Rabbit anti-mouse secondary antibody was applied at a concentration of 1:3000
and signals were detected using the enhanced chemiluminescent technique (Boehringer
Mannheim).

Northern Blot. 10 pg total RNA was separated on a 1% denaturing gel, transferred to
nitrocellulose filters, and hybridized to 32P-labelled cDNA fragments at 42°C in 50%
formamide. The filters were washed at in high stringency 0.1% SDS and 0.1X SSC at
55°C and autographed. Blots were probed with a 600-bp mouse LF probe cloned in our
laboratory.

Quantitative PCR (Q-PCR). cDNA was prepared as above and adjusted to concentration
of 10 ng/pL. 2 pL sample cDNA was incubated with lOOng of appropriate primers and
25 pL iQ SYBR Green Supermix (Bio-Rad) to a total volume of 50pL. PCR was
performed on a Bio-Rad Thermocycler at appropriate annealing conditions for a total of
40 cycles.
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Results

CDP shRNA constructs were first tested for their ability to reduce CDP levels by
transient transfection in fibroblast cell lines. NIH-3T3 cells are murine fibroblast cells
that express little endogenous CDP in whole cell lysates. Cotransfections of CDP
expression plasmids with two different shRNA constructs successfully decreased
expression of ectopically expressed CDP as demonstrated by both western blot and RTPCR (Figure 6). I have found that the shRNA at the 5’ end of the RNA transcript
(shRNA 1) is the most efficient at knocking down gene expression by RT-PCR.
However, by western blot it appears that the shRNA located at the 3’ end of the RNA
transcript was more efficient at CDP knock-down. The combination of the two plasmids
appears to be even more efficient at decreasing CDP levels. Three human CDP shRNA
constructs were also tested in HeLa cells with similar results (data not shown).
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Figure 6. Western blot and RT-PCR demonstrate decrease in CDP expression with
shRNA constructs in NIH 3T3 cells. NIH 3T3 cells were transiently transfected with
murine CDP expression plasmid alone, and CDP in combination with shRNA vectors.
(A) Western blot of transfected NIH 3T3 cells shows decreased CDP expression with
shRNA vectors. (B) RT-PCR also shows decreased levels of CDP expression in cells
containing shRNA 1.

Although many cell lines have been shown to express endogenous CDP, it is found at
very low levels in whole cell extracts, which is characteristic of transcription factors. To
assess the expression of endogenous CDP in human and mouse myeloid cells, I
performed a western blot using NB4 whole cell extracts, as well as whole cell extracts
and nuclear extracts of 32D cells (Figure 7). NB4 cells show endogenous expression of
CDP on western blot with whole cell extracts. CDP is undetectable in whole cell lysates
of 32D cells, but is easily detected in nuclear extracts.
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Figure 7. Western blot of NB4 and 32D cells for CDP. Lane 1 NB4 whole cell
extracts uninduced. Lane 2 NB4 whole cell extract induced with ATRA day 3. Lane 3
32D nuclear extract uninduced. Lane 4 32D nuclear extract induced with G-CSF day 4.
Lane 5 32D whole cell extract uninduced. Lane 6 32D whole cell extract induced with
G-CSF day 4.

A high degree of cell death is seen after induction of 32Dcl3 cells, reflecting stochastic
variation in the level of G-CSF expression. To alleviate this problem, 32Dwtl8 cells
have been previously generated. These cells express a chimeric G-CSF receptor with the
intracellular domain of the G-CSF linked to the extracellular erythropoietin binding
domain of the erythropoietin receptor. As these cells exhibit much less cell death on
differentiation with erythropoietin, I used 32Dwtl8 cells to generate stable cell lines.

After generating a pooled population of CDP shRNA expressing cells, I assessed the
growth characteristics of control and CDP shRNA containing 32Dwtl8 cells by cell
counting (Figure 8). 32Dwtl8 cells expressing the shRNA 1 construct do not have
different growth characteristics than those containing the empty MigRl vector. Cells in
regular GM continue to grow at an exponential pace, while cells induced to differentiate
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with EPO in IM have a longer doubling time. Those cells that were maintained in IM
without IL-3 did not grow, and were too few to count after 3 days.

MigRI GM
-•—shRNAI GM
MigRI IM + EPO
ShRNAI IM+EPO
MigRI IM
shRNAI IM

Figure 8. Growth curve of 32Dwtl8 cells transfected with MigRI vector alone
versus shRNA 1. 32Dwtl8 cells are an IL-3 dependent cell line which undergoes
differentiation along the neutrophil lineage upon induction with EPO in the absence of
IL-3. Cells transfected with shRNA remain IL-3 dependent, as evidenced by lack of
growth in IL-3 deficient IM. Transfected cells show no significant differences in growth
characteristics in GM and upon induction with EPO.

After cells were sorted twice for GFP, I performed RT-PCR to look at LF in uninduced
and induced cells. After 22 cycles of PCR, lactoferrin remained undetectable in
uninduced cells containing the MigRI vector (Figure 9). MigRI cells then showed
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normal upregulation of LF following induction with EPO. However, the cells containing
CDP shRNA did show expression of LF at day 0.
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Figure 9. RT-PCR demonstrates LF expression at day 0 in 32Dwtl8 cells expressing
shRNA 1. 32Dwtl8 cells are induced to differentiate with EPO and are shown at day 0
and day 4. Expression of LF at day 0 is not seen in cells expressing MigRI vector alone,
but is seen in cells expressing shRNA 1 construct. Both cells express LF following
induction with EPO.

To further quantify this difference in LF expression in day 0 cells, I performed a northern
blot on the same cells. Again, LF expression was absent in uninduced cells containing
MigRI alone (Figure 10). LF was normally upregulated in these cells by day 4.
However, in CDP shRNA cells LF expression was again seen in day 0 cells.
Densitometry analysis was then performed, and demonstrated a 14-fold increase in LF
expression at day 0. Quantitative expression of LF at day 4 was unchanged.
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Figure 10. Northern analysis demonstrates increased LF expression at day 0. (A)
RNA extracts from wtl8 cells transfected with MigRI and shRNAI were analyzed by
northern blot. LF expression is seen at day 0 in cells expressing shRNA, but not in cells
expressing MigRI vector alone. (B) Densitometry analysis of northern blot shows a 14fold increase in LF expression at day 0 in shRNA expressing cells relative to MigRI.
Relative expression of LF at day 4 remains unchanged.

To characterize the effect of CDP knock-down in other CDP-regulated genes I performed
Q-PCR of cDNAs from MigRI and CDP shRNA cell lines for CDP, LF, C/EBPs, and
gp91-phox. Q-PCR demonstrated a 3.9-fold decrease in CDP expression with
approximately a 12-fold increase in LF expression (Figure 11). Expression of C/EBPc
and gp91-phox was unchanged following CDP knock-down.
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Figure 11. Q-PCR demonstrates decreased CDP expression and increased LF
expression in shRNA clone relative to MigRl controls. Q-PCR confirms a 3.9-fold
decrease in CDP expression in shRNA expressing cells relative to MigRl cells at day 0.
LF expression is also increased 11.8-fold relative to MigRl. Expression of other CDPregulated genes such as gp91-phox and C/EBP epsilon remains unchanged.

22

Discussion

Generation of cell lines
I employed both positive and negative selection strategies in an attempt to create stable
cell lines expressing CDP shRNA. I performed cotransfections of my shRNA constructs
in the MigRl vector (shRNA 1, shRNA 2, and a combination of shRNA 1+2) with
empty pBabe-puro vector in a 10:1 ratio, and selected these cells in puromycin to
generate stable cell lines. However, given that 32Dwtl8 cells have a very low
transfection efficiency, on initial inspection of these cells I saw very few GFP-expressing
cells. In addition, after initial high rates of cell death upon addition of puromycin, the
transfected cells did not regrow.

The shRNA PCR fragment itself also contains a gene for zeocin resistance (Figure 4).
Again, 32Dwtl8 cells transfected with shRNA constructs did not regrow following
addition of zeocin. In conversations with other groups who used the same technique to
generate shRNA constructs for various target genes, they have similarly identified
difficulties in selecting with zeocin. Possible difficulties with the zeocin resistance gene
include inadequate expression or modification of the gene locus which do not allow
resistance to zeocin.

Since the shRNA construct is in the GFP-containing MigRl vector, we performed flow
cytometry sorting for GFP expression as an alternative to antibiotic selection. This
demonstrated the very low transfection efficiency of 32Dwtl8 cells, since only 0.35-
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0.55% of cells had GFP expression by flow cytometry. GFP may be expressed at low
levels undetectable by microscopy, or the U6 shRNA promoter may compete with the
LTR promoter which drives GFP expression. The latter is unlikely, since the shRNA is
driven from a RNA polymerase III promoter and GFP expression is driven from a RNA
polymerase II promoter (see Figure 5). This positive selection for GFP was the most
fruitful method to produce cells stably expressing CDP shRNA. The second sort by flow
cytometry yielded adequate purity to allow analysis of the cell lines, as approximately
70% of the cells were then GFP positive. The third flow cytometry sort generated cells
that were 99.97% GFP positive, allowing for generation of the final data. During all
FACS analysis, strict gating criteria were used in order to maximize the number of GFP
positive cells. This strict criterion allows for the possibility that even more cells were
GFP positive, albeit at lower levels of expression.

Cell Growth
After cells were sorted for the third time, they continued to grow normally for
approximately 2 weeks, then died rapidly. After repeating flow cytometry several times,
the cells continued to die when they were approximately 99% GFP positive. Cells grown
in the same growth medium and incubator that were not sorted a third time, and were thus
approximately 70% GFP positive, continued to maintain normal doubling times and
growth characteristics. These cells remained approximately 70% GFP positive after a
period of growth in culture, suggesting that GFP negative cells do not outgrow those
expressing GFP. A trans-effect whereby the GFP negative cells support growth of GFP
positive cells is not likely, as CDP is not known to have any extracellular effects. One
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hypothesis is that a minimal amount of CDP is essential for normal growth and cell
division. When no CDP is available to the cell, it will cease growth. Since CDP is
known to have many roles within the cell and at different times in differentiation, this
could mean that CDP is essential for proper cell growth and division.

In addition to generating a pooled population of cells expressing the CDP shRNA
construct, a monoclonal population was generated by sorting single cells into wells on
96-well plates. This was performed after the second enrichment for GFP. Single cell
clones were successfully generated, and several clones were expanded. After Q-PCR
testing of these clonal cell lines, it was apparent that some cell lines repressed CDP
expression better than others. Q-PCR analysis of these clones showed that they were also
the most efficient at upregulating LF expression. However, after approximately one
week in culture, clones with the lowest levels of CDP ceased to grow and began to die.
Data from these cell clones and from cell pools discussed above suggest that CDP may
indeed have an impact on cell growth. Very low or absent levels of CDP expression may
contribute to an apoptotic signal within the cell. Alternatively, high level expression of
CDP-regulated genes such as LF or other yet unknown factors may negatively influence
the growth curve of cells lacking CDP. These possibilities are being actively investigated
in the laboratory.

As it has been suggested that CDP may be a tumor suppressor gene product, I performed
cell counts to generate a growth curve for cells containing CDP shRNA and MigRl
alone. Since this was impossible to perform on the clonal cell populations with the
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lowest levels of CDP, I performed the analysis on pooled cell populations after the
second enrichment for GFP. No significant differences in growth characteristics were
seen between the two cell types. Cells in growth medium continued to divide
exponentially while the growth of those induced to differentiate exhibited a plateau in
growth. This was expected, as cells lose proliferative capacity as they differentiate. In
addition, CDP shRNA containing cells remain IL-3 dependent. If CDP were indeed a
tumor suppressor, one possible effect of repressing CDP could be that this IL-3
dependent cell line could become independent of IL-3. Our results do not support this
hypothesis, as cells quickly died in the absence of IL-3. The theory that CDP is a tumor
suppressor is not supported here, although much more data are required to fully analyze
this potential role. However, this is potentially at odds with the data that show growth
inhibition in both clonal and pooled cell populations with highly effective CDP knock¬
down. Although the knock-down of CDP did not change initial growth characteristics of
the cells, the possibility exists that cells cannot grow and divide for a long period of time
without CDP. In addition, intermediate levels of CDP expression may be adequate to
permit cell growth while allowing LF expression.

Effect of CDP knock-down
CDP is known to be expressed in actively dividing cells, and is thought to repress the
expression of genes required in terminally differentiated cells. Although preliminary
studies did not suggest that CDP overexpression affects morphologic differentiation, the
effect of loss of CDP expression remains unknown. Cytospins of uninduced and induced
cells did not show any morphological difference between control cells and CDP knock-
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down cells. It is likely that morphological differentiation and chromatin condensation is
controlled by different mechanisms than biochemical maturation.

Western blot data showing decreased CDP expression in cells containing CDP shRNA is
supported by Q-PCR data. One single cell clone containing shRNA 1 indicated a 4-fold
decrease in CDP expression. Other single-cell clones also confirmed this data, albeit
with varying levels of CDP knock-down. RNAi is known to generate clones with
varying levels of expression. As previously mentioned, cells with the highest level of
CDP knock-down did not grow long enough to expand for complete analysis. For this
reason, I tested many clones before picking a few which best repressed CDP expression
while maintaining adequate cell growth.

The RT-PCR data show that LF is undetectable in control MigRl clones after 22 cycles
of PCR, and is expressed at day 4 following induction. This is expected, as immature
wild-type myeloid cells do not express SGPs until they are induced to differentiate. SGP
expression can normally be seen following induction with a differentiating agent.
However, in the CDP shRNA cell clones we can see expression of LF at day 0. This
suggests that CDP may be the major repressor of LF expression in maturing granulocytes.

Although CDP knock-down has the effect of upregulating LF expression at day 0, the
expression of LF at day 4 of induction was unchanged from control cells. This was a
somewhat unexpected result, since it has been clearly shown that C/EBPc, a transcription
factor expressed in myeloid progenitors beyond the promyelocyte stage, is an important
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inducer of SGP expression. This result could be accounted for in a few ways. The main
transactivator of LF expression, C/EBPs, is expressed prior to induction of
differentiation. If CDP is indeed the sole repressor of LF, then one could postulate that
releasing the cell from CDP regulation following induction of differentiation may put the
cell at maximum producing capacity for production of LF. If this were the case, LF
expression in day 4 control cells would be at its maximum level. Indeed, CDP knock¬
down cells may also be at their maximum production capacity in their uninduced state.

Another reason we may detect similar levels of LF expression in day 4 cells is that the
sensitivity for detecting these high levels of expression may be low. Densitometry is not
sensitive for detecting high levels of expression, as the blot may appear overexposed. It
may be necessary to examine a less exposed blot to reevaluate this comparison. However,
Q-PCR has the ability to detect more subtle changes in expression, and we can confirm
the data by Q-PCR.

CDP shRNA single cell clones were also tested for expression of other CDP regulated
proteins, such C/EBPs and gp91-phox. No changes in expression of C/EBPs and gp91phox were seen in these cell lines. This may suggest that genes expressed earlier in
development may have a more complex mechanism of negative regulation. As CDP will
still be expressed in the cell up to the point of LF expression, these genes may require the
removal of an additional negative regulator to allow their expression. CDP is also a
complex protein, with a variety of mechanisms of action. Different combinations of cut
repeats and the homeodomain, in addition to the recruitment of histone deacetylaces and
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phosphorylation, have been proposed as possible mechanisms of action. While it appears
by both PCR and western blot that we are able to knock-down the entire protein, it may in
fact be that we are knocking down only the part of the protein responsible for repressing
LF expression. Alternatively, the small amount of CDP remaining in the cell may have a
higher affinity for the early promoters. This change in affinity may be determined by the
post-translational modifications discussed above.

Human Cell Lines
I also generated three shRNA constructs targeting the human CDP gene, with the goal of
expression in NB4 cells. NB4 are a human cell line which contains the t(15:17) PMLRARa translocation. These cells do not express SGPs following induction to
differentiate, and CDP has been found to remain bound to the LF promoter following
induction. However, morphological differentiation is not affected. We have previously
hypothesized that one of the changes associated with leukemic transformation is a
disruption of the post-translational modification of CDP, as reflected in the failure to
release CDP binding to the LF promoter upon induced maturation. We hypothesized that
removal of CDP would permit expression of LF and the other SGPs in this cell line.
However, we were unable to generate even a pooled cell population of human CDP
shRNA-containing NB4 cells. NB4 cells were appropriately transfected and sorted for
GFP expression. These cells were expanded following the first enrichment for GFP, but
following the second selection, cells ceased to proliferate. This was attempted several
times by several different members of the laboratory without success. We may attempt to
generate these cells using antibiotic selection, or by cloning very early in methylcellulose.

.
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However, CDP expression in these cells may be required for cell growth and we may
have to explore an alternative approach for analyzing the role of CDP in NB4 cells.

Conclusions
Although the role of human CDP knock-down has yet to be explored, I have successfully
shown that both human and murine CDP shRNA constructs are effective at knocking
down CDP expression in fibroblast cell lines. Expression of LF can be seen by RT-PCR,
Q-PCR and northern blot in uninduced 32Dwtl8 cells containing shRNA constructs,
suggesting that CDP plays a critical role in the negative regulation of LF. However,
expression of other CDP-regulated genes, such as gp91-phox and C/EBPe remains
unchanged. This suggests that LF expression reflects the direct modulation of CDP
binding to its promoter, not an indirect effect of C/EBPs expression. The data on the role
of CDP in cell growth have not been fully explored. Data from pools of transfected cells
does not seem to support the theory that CDP may function as a tumor suppressor, yet
low or absent levels of CDP seem to contribute to a cell death phenotype in both
32Dwtl8 and NB4 cells. The results suggest that CDP can function as the sole negative
regulatory element for LF gene expression, and that relief of CDP repression can increase
LF expression independent of increased binding of positive regulatory factors.
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Future Directions

To elucidate some of the more subtle differences in gene expression, we will perform
cDNA microarray analysis using a myeloid specific cDNA microarray generated in the
Berliner Lab in collaboration with Dr. Arch Perkins (Dept of Pathology, Yale University
School of Medicine). The results of this microarray will shed light on all genes regulated
by CDP during myeloid differentiation, and will provide valuable and more complete
information on the role CDP plays in the developing neutrophil. From here, we can
further direct our studies on neutrophil-specific gene expression.

Human NB4 cells, which harbor the t(l 5; 17) PML-RARa translocation, do not express
SGPs even after induction to differentiate with ATRA. However, morphological
differentiation is not affected. In these cells, CDP has been found to continually bind to
the LF promoter following morphological differentiation. I have generated three human
CDP shRNA constructs and tested them for CDP knock-down in HeLa cells. However,
we have encountered difficulty in placing these constructs in NB4 cells. Stable NB4 cell
lines expressing these constructs need to be generated, and a similar analysis of NB4
CDP shRNA cell lines will be conducted. We hypothesize that the knock-down of CDP
in these NB4 cells will allow expression of LF as well as other SGPs.
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